10-Q: Trulieve Cannabis Corp. Q1 2026 Financial Update

Trulieve Cannabis Corp. reports a decrease in revenue for Q1 2026 compared to Q1 2025, primarily due to retail price compression, while Adjusted EBITDA shows a slight decline.

Summary

• Revenue for the first quarter of 2026 was $286.8 million, a decrease of 4% from $297.8 million in the first quarter of 2025.
• Gross profit decreased by 7% to $170.1 million, with gross margin declining from 61.5% to 59.3%.
• Selling, general, and administrative expenses decreased by 12% to $104.9 million, largely due to reduced campaign and political contributions.
• Net income from continuing operations was $3.4 million, a significant improvement from a net loss of $32.1 million in the prior year period.
• Adjusted EBITDA was $100.4 million, a decrease of 8% from $109.2 million in Q1 2025, reflecting lower revenue.
• The company ended the quarter with $352.9 million in cash and cash equivalents, indicating sufficient liquidity for the next 12 months.
• The company has applied for DEA licenses in several states following the rescheduling of medical marijuana to Schedule III, anticipating federal legality for its medical operations in those states.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, with a notable improvement in net income from continuing operations and a strong cash position, offset by declining revenues and Adjusted EBITDA.

Positives

• Net income from continuing operations turned positive, reaching $3.4 million in Q1 2026, a substantial improvement from a net loss of $32.1 million in Q1 2025.
• Selling, general, and administrative expenses were reduced by 12% to $104.9 million, driven by a significant decrease in campaign and political contributions.
• Cash and cash equivalents increased to $352.9 million, providing a strong liquidity position.
• The company is pursuing federal legality for its medical operations in several states following the rescheduling of cannabis to Schedule III.
• Wholesale and other revenue increased by $5.8 million, indicating growth in partnerships.

Negatives

• Total revenue decreased by 4% to $286.8 million, primarily due to a $16.8 million decrease in retail revenue.
• Gross profit decreased by 7% to $170.1 million, and gross margin declined to 59.3% from 61.5%.
• Adjusted EBITDA decreased by 8% to $100.4 million, reflecting the decline in revenue.
• Inventories remained relatively flat at $242.3 million, showing no significant change from the previous quarter.
• The company continues to face price compression in its retail segment.

Risks

• Adult use cannabis remains illegal under U.S. federal law, posing risks of federal proceedings and civil asset forfeiture.
• The company may not be able to adequately protect its intellectual property due to the federal illegality of adult use cannabis.
• Potential for criminal prosecution or civil liabilities under RICO due to the federal illegality of adult use cannabis operations.
• Strict enforcement of federal law regarding adult use of cannabis could impede business plans.
• The company is subject to ongoing examinations by taxing authorities, including proposed assessments for taxes, interest, and penalties.
• The company faces intense competition in the cannabis industry, with potential for increased competition from larger, better-financed competitors.
• Maintaining cannabis licenses and obtaining new ones in a highly regulated environment presents ongoing challenges.

Future Outlook

The company believes its existing cash balances will be sufficient to meet anticipated cash requirements for at least the next 12 months. Future requirements may be funded through ongoing operations or debt/equity financings. The company is also pursuing DEA licenses to align its medical operations with federal legality following the rescheduling of medical marijuana.

Management Comments

• The decrease in revenue was driven by a $16.8 million decrease in retail revenue partially offset by a $5.8 million increase in wholesale and other revenue.
• The decrease in the current period expenditures compared to the prior year comparable period reflects lower campaign and political contributions, totaling $9.5 million in the current period compared to $23.0 million in the prior year period.
• The decrease in the provision for income taxes was primarily driven by the Company not applying IRC Section 280E for the 2026 taxable year, where the prior period included the impact of IRC Section 280E.
• The Company has applied for DEA licenses in Florida, Georgia, Pennsylvania and West Virginia, with the expected effect that the Companys operations in those medical-only states are federally legal.

Industry Context

StockSavvy.ai notes that Trulieve's Q1 2026 results reflect ongoing industry trends of retail price compression and a strategic shift towards wholesale growth. The company's proactive approach to federal rescheduling of medical cannabis is a significant development for the sector.

Comparison to Industry Standards

• Trulieve's gross margin of 59.3% in Q1 2026 is within the typical range for vertically integrated cannabis operators, though it has seen a slight decline from the previous year.
• The company's Adjusted EBITDA margin of 35.0% is a strong indicator of operational efficiency within the cannabis industry, though it has also experienced a slight decrease.
• The significant reduction in SG&A expenses, particularly campaign and political contributions, aligns with a broader industry trend of focusing on core operational efficiencies rather than extensive political lobbying, especially in light of evolving federal regulations.

Legal Proceedings

• The IRS issued Revenue Agent Reports in September 2025 proposing assessment of taxes, interest, and penalties for some subsidiaries. Trulieve is disputing these proposed liabilities and believes it will prevail, though the position does not yet meet ASC 740 recognition thresholds for tax years prior to 2026. The proposed penalty amount of approximately $38.1 million is not included in uncertain tax position liabilities, and Trulieve believes these penalties are without merit.

Related Party Transactions

• The company rents an asset from an entity directly owned in part by the CEO and Chair of the board, with expenses of $0.1 million for Q1 2026.
• The company leases a cultivation facility and corporate office from an entity indirectly owned by the CEO, a former board member, and another board member. Related party lease liabilities totaled $0.443 million as of March 31, 2026.

Stakeholder Impact

• Shareholders may see a mixed impact due to declining revenue and Adjusted EBITDA, but a positive net income and strong liquidity position.
• Employees may be impacted by continued focus on operational efficiencies and potential cost streamlining.
• Suppliers and creditors are likely to be positively impacted by the company's strong cash position and continued operations.
• Customers may experience continued price compression in retail, but benefit from a wide range of products and services.

Next Steps

• Continue to focus on new and expanded relationships with wholesale partners.
• Pursue DEA licenses in Florida, Georgia, Pennsylvania, and West Virginia to achieve federal legality for medical operations.
• Monitor and adapt to evolving federal and state regulations regarding cannabis.
• Continue to invest in infrastructure and technology to support scaled operations.
• Manage price compression in the retail segment through operational efficiencies and product mix.

Key Dates

Recommendation

The company shows signs of operational improvement with positive net income from continuing operations and a strong cash position. However, declining revenues and Adjusted EBITDA, coupled with ongoing risks related to federal illegality and tax disputes, warrant a cautious 'hold' recommendation until clearer signs of sustained revenue growth and regulatory clarity emerge.

Keywords

Trulieve Cannabis Corp., Form 10-Q, Quarterly Report, Cannabis, Multi-state operator, Revenue, Adjusted EBITDA, Financial Results, SEC Filing, Medical Cannabis, Adult-use Cannabis